市傳內地第二輪「4+7」仿製藥全國招標將開啟
據內地《金融界》報道,上周五晚上開始於內地一份「4+7」(4個直轄市加上7個省會城市)藥品集中採購座談會紀要在業內流傳,並引起了業內的高度關注。還有一份內蒙古興安盟用55種輔助用藥的消息在業內流傳,具有風向標意義的這個舉動同樣引起了醫藥界的高度關注。
座談會紀要顯示,7月12日下午國家醫保局在上海召集相關部門和仿制藥企業舉行座談。這個消息尚未得到官方的正式確認,但從企業處得到了印證。座談會紀要透露出的信息,與此前市場傳聞有較大出入。此前市場傳聞「4+7」城市要全面鋪開,在去年首次招標的25品種之上大量增加新的品種。
紀要透露的信息是,第二輪招標品種仍是先前的25個,但招標的範圍要從「4+7」城市拓展到全國所有省份及地區,包括全部地區的公立醫院、定點民營醫院、軍隊醫院,並拿出全國用量的70%來招標。這個變化,給25個品種以外的藥企一絲喘息的機會,也給25個品種之內的藥企擴大供給量及重新上車的機會。
根據4+7藥品集中採購座談會紀要,第二輪招標計劃中的一個重要內容,是將在全國執行3家仿製藥通過一致性評價後不得採購未過評藥品的政策,不但不採購,而且不報銷。原本首輪4+7藥品集中採購後,一些仿制藥企業出現了觀望等待的態度,現今國家醫保局明確嚴格執行仿制藥一致性評價政策,不去做一致性評價就沒有市場機會了,仿製藥企業會加快一致性評價的進程。(wl/u)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.